EYPT EyePoint Pharmaceuticals
Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
23 Nov 21
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Kevin Peters, Michael Allen Flynn
Filed: 17 Apr 20
Patents are sorted by USPTO publication date, most recent first